In spite of a positive correlation between the S1P metabolic enzymes and inflammation in RCC, globally targeting S1P using the anti-S1P monoclonal antibody sonepcizumab failed in a phase II clinical trial of metastatic renal cell carcinoma [45]. The gene discussed is MBTPS1; the disease is renal cell carcinoma.